SCP
VRTX icon

Sivia Capital Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Sivia Capital Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-678
Closed -$307K – 631
2025
Q4 		$307K Sell
678
-2
-0.3% -$862 0.06% 401
2025
Q3 		$266K Buy
680
+23
+4% +$9.61K 0.08% 360
2025
Q2 		$292K Sell
657
-69
-10% -$31.8K 0.1% 291
2025
Q1 		$352K Buy
726
+68
+10% +$31.7K 0.16% 129
2024
Q4 		$265K Sell
658
-151
-19% -$70K 0.13% 134
2024
Q3 		$376K Buy
809
+1
+0.1% +$480 0.22% 87
2024
Q2 		$379K Buy
808
+85
+12% +$36.9K 0.25% 72
2024
Q1 		$302K Sell
723
-3
-0.4% -$1.27K 0.21% 108
2023
Q4 		$295K Buy
+726
New +$268K 0.23% 95

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Sivia Capital Partners's VRTX Position: Q1 2026 in Review

Sivia Capital Partners sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 678 shares — an estimated $307K sold.

Sivia Capital Partners first reported a position in VRTX in Q4 2023 and held it in 9 quarters. The position peaked at $379K in Q2 2024. 1,695 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Sivia Capital Partners reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Sivia Capital Partners sold 678 Vertex Pharmaceuticals shares in Q1 2026, an estimated $307K.
  • Sivia Capital Partners first reported a position in Vertex Pharmaceuticals in Q4 2023 and held it in 9 quarters.
  • Sivia Capital Partners's Vertex Pharmaceuticals position peaked at $379K in Q2 2024.
  • 1,695 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Sivia Capital Partners's 13F filing for Q1 2026, filed 13 May 2026.